The company's asset base is heavily skewed toward cash, which reached $19.0 million in 2026Q1 following capital raises, yet this liquidity is offset by a long-term accumulation of $61.3 million in retained earnings deficits.
| Total Current Assets | 19.38M | 12.4M | 824.28K | 1.29M | 1.7M | 732.2K | 97.13K | 218.51K |
| Cash & Short-Term Investments | 19M | 12.02M | 453.66K | 1.02M | 1.47M | 432.53K | 14.98K | 128.16K |
| Cash Only | 19M | 12.02M | 453.66K | 1.02M | 1.47M | 432.53K | 14.98K | 128.16K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 40.58K | 29.68K | 18.33K | 13.42K | 18.65K | 6.28K | 22.5K | 14.7K |
| Days Sales Outstanding | 144.35 | 143.05 | 146.29 | 64.98 | 112.64 | 38.02 | 168.82 | 199.42 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 330.99K | 25K | 133.9K | 152.22K | 59.56K | 20K | 0 | 0 |
| Total Non-Current Assets | 1.26M | 1.28M | 1.3M | 1.17M | 1.21M | 1.16M | 1.19M | 1.21M |
| Property, Plant & Equipment | 22.87K | 24.17K | 5.5K | 1.78K | 3.35K | 12.64K | 25.62K | 48.51K |
| Fixed Asset Turnover | 4.67x | 3.13x | 8.31x | 42.31x | 18.06x | 4.77x | 1.90x | 0.55x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.24M | 1.25M | 1.29M | 1.17M | 1.21M | 1.14M | 1.17M | 1.16M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 20.64M | 13.67M | 2.12M | 2.46M | 2.91M | 1.89M | 1.29M | 1.43M |
| Asset Turnover | 0.01x | 0.01x | 0.02x | 0.03x | 0.02x | 0.03x | 0.04x | 0.02x |
| Asset Growth % | 1260.85% | 543.87% | -13.67% | -15.61% | 54.26% | 46.27% | -9.69% | - |
| Total Current Liabilities | 986.21K | 837.29K | 1.15M | 3.19M | 688.67K | 7.62M | 8.38M | 3.13M |
| Accounts Payable | 587.29K | 324.47K | 531.6K | 760.53K | 457.56K | 1.06M | 859.53K | 501.03K |
| Days Payables Outstanding | 1.08K | 399.69 | 1.5K | 3.67K | 2.56K | 5.59K | 4.74K | 2.89K |
| Short-Term Debt | 0 | 0 | 0 | 1.13M | 0 | 2M | 2.38M | 515.55K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 398.92K | 459.67K | 543.12K | 768.87K | 165.95K | 0 | 2M | 2.02M |
| Current Ratio | 19.65x | 14.81x | 0.71x | 0.40x | 2.47x | 0.10x | 0.01x | 0.07x |
| Quick Ratio | 19.65x | 14.81x | 0.71x | 0.40x | 2.47x | 0.10x | 0.01x | 0.07x |
| Cash Conversion Cycle | -938.09 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 986.21K | 837.29K | 1.15M | 3.19M | 688.67K | 7.62M | 8.38M | 3.13M |
| Total Debt | 0 | 0 | 0 | 1.13M | 0 | 2M | 2.38M | 515.55K |
| Net Debt | -19M | -12.02M | -453.66K | 104.66K | -1.47M | 1.57M | 2.36M | 387.39K |
| Debt / Equity | 0.00x | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.29x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -12.06x | -7.07x | -3.69x | -9.39x | -28.70x | -803.66x |
| Total Equity | 19.65M | 12.84M | 970.06K | -728K | 2.23M | -5.73M | -7.08M | -1.7M |
| Equity Growth % | 2409.85% | 1223.13% | 233.25% | -132.7% | 138.85% | 19.12% | -316.21% | - |
| Book Value per Share | 9.23 | 24.12 | 1028.87 | -11825.83 | 52761.77 | -115468.66 | -142762.87 | -34300.81 |
| Total Shareholders' Equity | 19.65M | 12.84M | 970.06K | -728K | 2.23M | -5.73M | -7.08M | -1.7M |
| Common Stock | 25 | 9 | 0 | 8 | 5 | 9 | 68 | 68 |
| Retained Earnings | -61.35M | -58.5M | -51.26M | -44.28M | -39.37M | -31.89M | -25.93M | -20.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dilutive financing dependency
According to recent SEC filings, Aclarion’s total assets surged to $20.6 million in 2026Q1 from $2.1 million in 2024Q4, a shift driven entirely by external capital raises rather than organic asset accumulation or the successful scaling of its proprietary diagnostic software business model.
The rapid expansion of the balance sheet appears to be a defensive measure to offset persistent operating losses rather than a sign of business maturity. Investors should monitor whether this liquidity buffer can be converted into sustainable commercial traction before the cash is exhausted by ongoing R&D and regulatory overhead.
As reported in financial statements, Aclarion maintained $19.0 million in cash as of 2026Q1, providing a temporary liquidity cushion that contrasts sharply with the company's historical inability to generate positive operating cash flow or achieve a stable, recurring revenue stream from its NOCISCAN-LS diagnostic suite.
While the current ratio of 19.65 suggests a strong short-term position, this metric is heavily distorted by the recent influx of cash and the lack of significant current liabilities. The company remains highly vulnerable to liquidity shocks if the current burn rate is not mitigated by a rapid increase in paid clinical scan volumes.
Based on Aclarion's reported figures, the company’s retained earnings have deteriorated to -$61.3 million as of 2026Q1, reflecting a long-term pattern of value destruction that necessitates frequent reliance on dilutive equity financing to maintain the company's ongoing clinical and regulatory development efforts.
The negative retained earnings balance highlights the significant financial burden of the company's science-first strategy. Shareholders should be aware that the current equity base is largely a product of capital raises, which may continue to dilute existing ownership stakes if the company fails to reach a self-sustaining commercial inflection point.
As indicated by the balance sheet, Aclarion’s asset base is dominated by cash, with minimal investment in tangible property, plant, and equipment, which suggests that the company’s primary value is tied to intangible intellectual property that remains unproven in terms of broad market adoption.
The reliance on intangible assets and the absence of meaningful physical infrastructure may complicate future financing efforts, as there are few tangible assets to serve as collateral. This structure implies that the company's valuation is almost entirely dependent on the successful commercialization of its signal processing algorithms, representing a binary risk for investors.
Quick answers to the most common questions about buying ACON stock.
As of 2025, Aclarion, Inc. (ACON) had total assets of $13.7M including $12.4M in current assets.
Aclarion, Inc. (ACON) carries total debt of $0.0M, offset by $12.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Aclarion, Inc. (ACON) has total shareholders' equity (book value) of $12.8M ($24.12 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Aclarion, Inc. (ACON) reported a current ratio of 14.81x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.